Description: Bumrungrad Hospital Public Company Limited owns and operates healthcare-related entities in Thailand and internationally. The company offers diagnostic, therapeutic, and intensive care facilities in a medical center. Its outpatient clinics/centers include allergy, arrhythmia, behavioral health, breastfeeding, breast care, children, dental, diabetes, diagnostic, dialysis, digestive disease, emergency, eye, fertility and IVF, health screening, hearing and balance, heart valve, cancer, hyperbaric oxygen therapy, hypertension, joint replacement, liver, memory, men, nephrology, neuroscience, new life healthy aging, orthopedic, Parkinson's disease and movement disorders, perinatal, physical therapy and rehabilitation, plastic surgery, pulmonary, refractive surgery, robotic scoliosis and surgery, skin, sleep lab, spine, sports medicine and lifestyle, surgical, travel medicine, urology, vitalife, and women's, as well as ear, nose, and throat centers. In addition, the company is involved in the real estate assets holding activities; provision of clinical research services; distribution of pharmaceutical and medical goods in specialized stores; operation of personnel development and training center for healthcare services; and patient referral service business. It operates 580 beds and approximately 56 clinics/centers. The company was founded in 1980 and is headquartered in Bangkok, Thailand.
Home Page: www.bumrungrad.com
33 Sukhumvit Soi 3 (Nana Nua)
Bangkok,
10110
Thailand
Phone:
66 2 066 8888
Officers
| Name | Title |
|---|---|
| Ms. Linda Lisahapanya | Pres, MD & Exec. Director |
| Ms. Artirat Charukitpipat | Chief Exec. Officer |
| Ms. Oraphan Buamuang | Chief Financial Officer |
| Ms. Supawan Sirinuntawit | Accounting Mang. |
| Mr. Daniel Kastner | Chief Transformation Office & Head of IR |
| Dr. Aniello M. Sorrentino Ph.D. | Corp. Chief Strategy Officer |
| Mr. David T. Boucher FACHE | Chief Bus. Transformation Officer |
| Tanee Maneenut | Chief Bus. Devel. Officer |
| Ms. Rangsima Thongdee | Head of Internal Audit |
| Jeremy Ford | Laboratory Research & Technology Director of Bumrungrad International Hospital |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 34.0136 |
|---|---|
| Trailing PE: | 46.6154 |
| Price-to-Book MRQ: | 9.2234 |
| Price-to-Sales TTM: | 0.2576 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |